tiprankstipranks
Advertisement
Advertisement

DE:8F8 Stock Latest News

SynAct Pharma Publishes 2025 Annual Report on Inflammatory Disease Pipeline
Company AnnouncementsSynAct Pharma Publishes 2025 Annual Report on Inflammatory Disease Pipeline
2d ago
SynAct Pharma Raises Share Capital Through Directed Issue
PremiumCompany Announcements
SynAct Pharma Raises Share Capital Through Directed Issue
17d ago
SynAct Pharma Starts Phase 2 Dengue Trial of Resomelagon in Brazil
PremiumCompany Announcements
SynAct Pharma Starts Phase 2 Dengue Trial of Resomelagon in Brazil
22d ago
SynAct Pharma Targets RA Partnerships With BIO-Europe Spring 2026 Showcase
PremiumCompany Announcements
SynAct Pharma Targets RA Partnerships With BIO-Europe Spring 2026 Showcase
1M ago
SynAct Pharma Sets Capital Markets Day as It Enters Key Clinical Inflection Point
PremiumCompany Announcements
SynAct Pharma Sets Capital Markets Day as It Enters Key Clinical Inflection Point
1M ago
SynAct Pharma Raises SEK 51.9 Million in Directed Share Issue to Strengthen Runway and Deal Leverage
PremiumCompany AnnouncementsSynAct Pharma Raises SEK 51.9 Million in Directed Share Issue to Strengthen Runway and Deal Leverage
2M ago
SynAct Pharma Plans SEK 45 Million Directed Share Issue to Bolster Clinical Runway
Premium
Company Announcements
SynAct Pharma Plans SEK 45 Million Directed Share Issue to Bolster Clinical Runway
2M ago
SynAct Pharma Names New CFO Ahead of Pivotal Phase 2b Data
Premium
Company Announcements
SynAct Pharma Names New CFO Ahead of Pivotal Phase 2b Data
2M ago
SynAct Pharma Publishes 2025 Annual Results and Highlights R&D Focus
PremiumCompany Announcements
SynAct Pharma Publishes 2025 Annual Results and Highlights R&D Focus
2M ago
SynAct Pharma Advances SEK 5 Million Share Buyback, Reacquires 212,307 Shares
PremiumCompany Announcements
SynAct Pharma Advances SEK 5 Million Share Buyback, Reacquires 212,307 Shares
2M ago
SynAct Pharma Plans Capital Markets Day Ahead of Key Clinical Readouts
PremiumCompany Announcements
SynAct Pharma Plans Capital Markets Day Ahead of Key Clinical Readouts
2M ago
SynAct Pharma Hits Recruitment Milestone in Phase 2b Rheumatoid Arthritis Trial
PremiumCompany Announcements
SynAct Pharma Hits Recruitment Milestone in Phase 2b Rheumatoid Arthritis Trial
2M ago
SynAct Pharma Launches Phase 2 RESPIRE Trial of Resomelagon in Viral Respiratory Insufficiency
PremiumCompany AnnouncementsSynAct Pharma Launches Phase 2 RESPIRE Trial of Resomelagon in Viral Respiratory Insufficiency
3M ago
SynAct Pharma Names Long-Serving Finance Executive as Interim CFO
Premium
Company Announcements
SynAct Pharma Names Long-Serving Finance Executive as Interim CFO
3M ago
SynAct Pharma Launches Share Buyback to Optimize Capital Structure
Premium
Company Announcements
SynAct Pharma Launches Share Buyback to Optimize Capital Structure
3M ago
SynAct Pharma Leadership Enters Lock-Up Ahead of Key Clinical Milestones
PremiumCompany Announcements
SynAct Pharma Leadership Enters Lock-Up Ahead of Key Clinical Milestones
4M ago
SynAct Pharma Leadership Buys Shares as Key Rheumatoid Arthritis Milestone Nears
PremiumCompany Announcements
SynAct Pharma Leadership Buys Shares as Key Rheumatoid Arthritis Milestone Nears
4M ago
SynAct Pharma AB Appoints Nomination Committee for 2026 AGM
PremiumCompany Announcements
SynAct Pharma AB Appoints Nomination Committee for 2026 AGM
4M ago
SynAct Pharma to Attend J.P. Morgan Healthcare Conference for Strategic Engagements
PremiumCompany Announcements
SynAct Pharma to Attend J.P. Morgan Healthcare Conference for Strategic Engagements
4M ago
SynAct Pharma AB Implements New Share Option Program and Share Management Strategy
PremiumCompany AnnouncementsSynAct Pharma AB Implements New Share Option Program and Share Management Strategy
5M ago
SynAct Pharma to Present at Redeye Autoimmune and Inflammatory Diseases Event
Premium
Company Announcements
SynAct Pharma to Present at Redeye Autoimmune and Inflammatory Diseases Event
5M ago
SynAct Pharma Advances Resomelagon Phase 2b Study for Rheumatoid Arthritis
Premium
Company Announcements
SynAct Pharma Advances Resomelagon Phase 2b Study for Rheumatoid Arthritis
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >